| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $6.8M | — | -16.0% |
| SG&A Expense | $4.3M | — | -10.9% |
| Operating Income | -$14.6M | — | +1.8% |
| Income Tax | -$5.3M | — | — |
| Net Income | $35.9M | — | +338.9% |
| EPS (Basic) | $3.60 | — | +1158.8% |
| EPS (Diluted) | $2.88 | — | +947.1% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $18.2M | +212.7% | +133.7% |
| Short-term Investments | $0 | -100.0% | — |
| Current Assets | $25.6M | +11.7% | -24.4% |
| Total Assets | $26.6M | -71.5% | -75.1% |
| Current Liabilities | $8.8M | -79.7% | +4.9% |
| Total Liabilities | $11.0M | -91.5% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$7.6M | — | +20.6% |
| Capital Expenditures | $0 | — | -100.0% |
| Investing Cash Flow | $12.0M | — | +10.1% |
| Financing Cash Flow | $9.4M | — | — |
| Free Cash Flow | -$7.6M | — | +21.8% |
| -87.6% |
| Stockholders' Equity | $15.7M | +143.9% | -15.7% |